Page last updated: 2024-09-05

diflomotecan and Benign Neoplasms

diflomotecan has been researched along with Benign Neoplasms in 8 studies

Research

Studies (8)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	7 (87.50)	29.6817
2010's	1 (12.50)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Buil-Bruna, N; Garrido, MJ; Mangas-Sanjuan, V; Soto, E; Trocóniz, IF	1
Cendros, JM; Evans, TR; Falk, S; Graham, JS; Samuel, LM	1
Gelderblom, H; Kroep, JR	1
Maneely, D	1
de Jonge, MJ; Devlin, M; Gelderblom, H; Obach, R; Pentheroudakis, G; Principe, P; Pruñonosa, J; Salazar, R; Seguy, F; Twelves, C; van Hooije, C; Verweij, J	1
Osheroff, N	1
Cendrós, JM; Garrido, MJ; Obach, R; Peraire, C; Principe, P; Segura, C; Trocòniz, IF	1
de Jonge, MJ; McGovern, D; Obach, R; Principe, P; Scott, L; Soepenberg, O; Th Planting, AS; Twelves, C; Verweij, J	1

Reviews

2 review(s) available for diflomotecan and Benign Neoplasms

Article	Year
Diflomotecan, a promising homocamptothecin for cancer therapy. Expert opinion on investigational drugs, 2009, Volume: 18, Issue:1 Topics: Animals; Camptothecin; Clinical Trials as Topic; Humans; Neoplasms; Treatment Outcome	2009
Diflomotecan. Ipsen. IDrugs : the investigational drugs journal, 2004, Volume: 7, Issue:3 Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; DNA Topoisomerases, Type I; Drugs, Investigational; Enzyme Inhibitors; Humans; Neoplasms; Topoisomerase I Inhibitors	2004

Trials

3 trial(s) available for diflomotecan and Benign Neoplasms

Article	Year
Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Sep-15, Volume: 9, Issue:11 Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Biological Availability; Camptothecin; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms	2003
Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours. Cancer chemotherapy and pharmacology, 2006, Volume: 57, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Female; France; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Models, Biological; Multicenter Studies as Topic; Neoplasms; Neutropenia	2006
A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours. Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:3 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; DNA Topoisomerases, Type I; Drug Administration Schedule; Enzyme Inhibitors; Europe; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Topoisomerase I Inhibitors; Treatment Outcome	2007

Other Studies

3 other study(ies) available for diflomotecan and Benign Neoplasms

Article	Year
Semimechanistic cell-cycle type-based pharmacokinetic/pharmacodynamic model of chemotherapy-induced neutropenic effects of diflomotecan under different dosing schedules. The Journal of pharmacology and experimental therapeutics, 2015, Volume: 354, Issue:1 Topics: Antineoplastic Agents; Bone Marrow Cells; Camptothecin; Cell Cycle; Cell Proliferation; Clinical Trials, Phase I as Topic; Drug Administration Schedule; Humans; Models, Biological; Neoplasms; Neutropenia; Neutrophils; Stem Cells	2015
A multi-centre dose-escalation and pharmacokinetic study of diflomotecan in patients with advanced malignancy. Cancer chemotherapy and pharmacology, 2009, Volume: 63, Issue:5 Topics: Administration, Oral; Adolescent; Adult; Aged; Breath Tests; Camptothecin; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Erythromycin; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Neoplasms; Prognosis; Survival Rate; Tissue Distribution; Treatment Outcome; Young Adult	2009
Clinical Trials in Cancer-SMi Conference. 11-12 June 2003, London, UK. IDrugs : the investigational drugs journal, 2003, Volume: 6, Issue:7 Topics: Antineoplastic Agents; Camptothecin; Cancer Vaccines; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Erlotinib Hydrochloride; Humans; Molecular Structure; Neoplasms; Quinazolines; Treatment Outcome	2003